A breakthrough in genome engineering! The CRISPR/Cas9 (CRISPR-associated protein 9 nuclease) system uses a RNA-guided endonuclease technology which allows for inducing indel mutations, specific sequence replacements or insertions and large deletions or genomic rearrangements at any desired location in the genome. In addition, Cas9 can also be used to mediate up- or downregulation of specific endogenous genes or to alter histone modifications or DNA methylation.
CRISPR/Cas9 C-terminal monoclonal antibody (sample size)
DISCONTINUED 
Monoclonal antibody raised in mouse against the C-terminus of Cas9 nuclease (CRISPR-associated protein 9)
| Lot | 001 |
|---|---|
| Concentration | 2.2 µg/µl |
| Species reactivity | Streptococcus pyogenes |
| Type | Monoclonal |
| Purity | Protein G purified monoclonal antibody. |
| Host | Mouse |
| Storage Conditions | Store at -20°C; for long storage, store at -80°C. Avoid multiple freeze-thaw cycles |
| Storage Buffer | PBS containing 0.05 % Na-azide. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Applications | Suggested dilution | References |
|---|---|---|
| Western Blotting | 1:1,000 - 1:5,000 | Fig 1,2 |
| IP | 13 µg/IP | Fig 3 |
| IF | 1:200 | Fig 4 |
- Validation data
Figure 1. Western blot analysis using the Diagenode monoclonal antibody directed against CRISPR/Cas9
Western blot was performed on protein extracts from HeLa cells transfected with Cas9 using the Diagenode antibody against CRISPR/Cas9 (cat. No. C15200223). The antibody was used at different dilutions. The marker is shown on the left, position of the Cas9 protein is indicated on the right.
Figure 2. Western blot analysis using the Diagenode monoclonal antibody directed against CRISPR/Cas9
Western blot was performed on 20 μg protein extracts from Cas9 expressing HeLa cells (lane 1) and on negative control HeLa cells (lane 2) with the Diagenode antibody against Cas9 (cat. No. C15200223). The antibody was diluted 1:4,000. The marker is shown on the left, position of the Cas9 protein is indicated on the right.
Figure 3. IP using the Diagenode monoclonal antibody directed against Cas9
IP was performed on whole cell extracts (250 μg) from HeLa cells transfected with a Cas9 expression vector (lane 1 and 3), or untransfected cells (lane 2 and 4) using 13 μg of the Diagenode antibody against Cas9 (cat. No. C15200223). The immunoprecipitated proteins were subsequently analysed by Western blot. Lane 3 and 4 show the result of the IP, the input (15 μg) is shown in lane 1 and 2.
Figure 4. Immunofluorescence using the Diagenode monoclonal antibody directed against CRISPR/Cas9
HeLa cells expressing Cas9 under the control of the tight TRE promoter were fixed in methanol at -20°C, permeabilized with acetone at -20°C and blocked with PBS containing 2% BSA. The cells were stained with the Cas9 C-terminal antibody (cat. No. C15200223) diluted 1:200, followed by incubation with a donkey anti-mouse secondary antibody coupled to AF488. Nuclei were counter-stained with Hoechst 33342. Figure 4 shows the result in the presence (left) or absence (right) of doxycycline. - 出版物
How to properly cite our product/service in your work
We strongly recommend using this: CRISPR/Cas9 C-terminal monoclonal antibody (sample size) (Hologic Diagenode Cat# C15200223-14 Lot# 001). Click here to copy to clipboard.
Using our products or services in your publication? Let us know!
- 相关产品